Information  X 
Enter a valid email address

Amryt Pharma PLC (AMYT)

  Print      Mail a friend

Wednesday 19 February, 2020

Amryt Pharma PLC

Draft registration statement for US Nasdaq listing

RNS Number : 4847D
Amryt Pharma PLC
19 February 2020
 

19 February 2020
AIM: AMYT
Euronext Growth: AYP


AMRYT PHARMA PLC

("Amryt" or the "Company")

Amryt submits draft registration statement for US listing on the Nasdaq

Amryt, a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, announces today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission ("SEC") relating to the proposed listing of American Depositary Shares ("ADSs") representing Amryt ordinary shares on the Nasdaq stock market ("Nasdaq").

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). This announcement is being issued in accordance with Rule 135 under the Securities Act.

Certain statements contained in this press release constitute "forward-looking statements." These forward-looking statements represent the Company's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These statements include, but are not limited to, statements regarding the pursuit of the potential U.S. listing, including the timing and outcome of SEC and Nasdaq review, the timing and occurrence of any such listing and, if achieved, the expected benefits thereof. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company's control, including market and other conditions, that could cause actual results to differ materially from the intentions discussed in the forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, the Company does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all such factors.

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014.

Enquiries:


Amryt Pharma plc

+353 (1) 518 0200

Joe Wiley, CEO

Rory Nealon, CFO/COO


 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCBBGDDGBBDGGC

a d v e r t i s e m e n t